Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

NCT05686239 is registered in ClinicalTrials.gov with Recognify Life Sciences as lead sponsor.

NCT NCT05686239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05686239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Lead sponsor
Recognify Life Sciences
Phase
Phase 2
Overall status
Completed
Start date
December 8, 2022
Completion date
April 9, 2025
Enrollment
242 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, cognitive impairment associated with schizophrenia (cias), schizophrenia